MCID: ALL009
MIFTS: 50

Allergic Conjunctivitis

Categories: Eye diseases, Immune diseases

Aliases & Classifications for Allergic Conjunctivitis

MalaCards integrated aliases for Allergic Conjunctivitis:

Name: Allergic Conjunctivitis 12 14 69
Conjunctivitis, Allergic 42
Conjunctivitis Allergic 52

Classifications:



External Ids:

Disease Ontology 12 DOID:11204
MeSH 42 D003233
NCIt 47 C34506
UMLS 69 C0009766

Summaries for Allergic Conjunctivitis

Disease Ontology : 12 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.

MalaCards based summary : Allergic Conjunctivitis, also known as conjunctivitis, allergic, is related to lymphoma and asthma. An important gene associated with Allergic Conjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Alcaftadine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 72 Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the... more...

Related Diseases for Allergic Conjunctivitis

Diseases related to Allergic Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
id Related Disease Score Top Affiliating Genes
1 lymphoma 29.3 IFNG IL13 IL4 IL5
2 asthma 25.4 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
3 allergic rhinitis 11.2
4 conjunctivitis 11.0
5 pollen allergy 10.9
6 papillary follicular thyroid adenocarcinoma 10.7 IL5 RNASE3
7 cytoplasmic body myopathy 10.7 IL13 IL5
8 aortic arch interruption 10.7 IL13 IL5
9 cow milk allergy 10.7 IL13 IL4
10 crustacean allergy 10.7 IL5 RNASE3
11 penis agenesis 10.7 CCL11 IL5
12 orbit alveolar rhabdomyosarcoma 10.7 IL4 IL5
13 angioid streaks of choroid 10.7 IL4 IL5
14 hypercementosis 10.7 IL13 IL5
15 allescheriosis 10.7 IL4 IL5
16 urethral intrinsic sphincter deficiency 10.7 IL4 IL5
17 solitary cyst of breast 10.6 CCL11 IL5
18 chronic cholangitis 10.6 CCL11 IL4
19 myofibroma 10.6 IL13 IL5
20 subacute bacterial endocarditis 10.6 IL5 RNASE3
21 ileitis 10.6 ICAM1 IL4
22 myoclonic astatic epilepsy 10.6 IFNG IL4
23 histoplasmosis retinitis 10.6 IL4 IL5
24 eye accommodation disease 10.5 IFNG IL4
25 anterior dislocation of lens 10.5 CCL11 IL4 RNASE3
26 marasmus 10.5 IL4 IL5 RNASE3
27 thelaziasis 10.5 IFNG IL4
28 orbital plasma cell granuloma 10.5 IL4 IL5 RNASE3
29 exudative vitreoretinopathy 2, x-linked 10.5 IL13 IL5
30 indian tick typhus 10.5 IFNG IL13
31 toxic diffuse goiter 10.5 IL13 IL5 RNASE3
32 gastroschisis 10.5 IFNG IL5
33 nut allergy 10.5 IL4 IL5 RNASE3
34 liver leiomyoma 10.5 IL4 TLR3
35 esophagus small cell carcinoma 10.5 IL13 IL5
36 cherry allergy 10.5 IL13 IL4 IL5
37 abdominal tuberculosis 10.5 IL13 IL4 IL5
38 moved to 244450 10.5 ICAM1 IL13
39 lymphocytic gastritis 10.5 CCL11 IL5 RNASE3
40 glucose intolerance 10.5 IL13 IL4 IL5
41 spindle cell variant squamous cell breast carcinoma 10.5 IL13 IL4 IL5
42 hypercalcinuria macular coloboma 10.4 IFNG IL4
43 antley-bixler syndrome with genital anomalies and disordered steroidogenesis 10.4 CCL11 IL13 IL5
44 centronuclear myopathy 5 10.4 IFNG IL4
45 basidiobolomycosis 10.4 CXCL8 IL4
46 bartholin's duct cyst 10.4 CCL11 IL5 RNASE3
47 hypereosinophilic syndrome 10.4 IFNG IL5
48 oropharyngeal cancer, childhood 10.4 IFNG IL4
49 lymph node palisaded myofibroblastoma 10.4 CCL11 CXCL8
50 signet ring cell adenocarcinoma 10.4 IL5 RNASE3

Graphical network of the top 20 diseases related to Allergic Conjunctivitis:



Diseases related to Allergic Conjunctivitis

Symptoms & Phenotypes for Allergic Conjunctivitis

MGI Mouse Phenotypes related to Allergic Conjunctivitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 CCL11 HRH1 ICAM1 IFNG IL13 IL33
2 homeostasis/metabolism MP:0005376 9.81 TLR3 HRH1 ICAM1 IFNG IL13 IL33
3 digestive/alimentary MP:0005381 9.8 ICAM1 IFNG IL13 IL33 IL4 IL5
4 immune system MP:0005387 9.65 IFNG IL13 IL33 IL4 IL5 PTGDR2
5 respiratory system MP:0005388 9.17 CCL11 IFNG IL13 IL33 IL4 IL5

Drugs & Therapeutics for Allergic Conjunctivitis

Drugs for Allergic Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
2
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
4
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
5
Pheniramine Approved Phase 4 86-21-5 4761
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
7
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
8
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
9
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-14-8, 34580-13-7 3827
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
11
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
14
Dipivefrin Approved Phase 4 52365-63-6 3105
15
Tranilast Approved, Investigational Phase 4 53902-12-8 93543
16
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
18
Montelukast Approved Phase 4 158966-92-8 5281040
19
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
20 Racepinephrine Approved Phase 4
21
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
22
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
23
Maleic acid Experimental Phase 4 110-16-7 444266
24 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
25 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
26 Adrenergic Agents Phase 4,Phase 3,Phase 2
27 Adrenergic Agonists Phase 4,Phase 3,Phase 2
28 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
29 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antipruritics Phase 4,Phase 3,Phase 2,Phase 1
31 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1
34
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1 51-74-1 65513
35 Nasal Decongestants Phase 4,Phase 3,Phase 2,Phase 1
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
41 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
44 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2,Phase 1
46 Olopatadine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2
49 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
50 Antiemetics Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 182)

id Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
5 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
6 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
7 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
8 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
9 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
10 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
11 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
12 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
13 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
14 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
15 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
16 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 ELESTAT® (epinastine HCl ophthalmic solution) 0.05%
17 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
18 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
19 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Artificial tears
20 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
21 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
22 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
23 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
24 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
25 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
26 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
27 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
28 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
29 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
30 The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
31 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
32 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
33 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
34 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Completed NCT02256553 Phase 4 Rescue Medication
35 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4 Grazax
36 Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Recruiting NCT03186755 Phase 4 Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1%
37 A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Active, not recruiting NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
38 Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan Terminated NCT00276445 Phase 4 beta-1,3-glucan
39 Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification Terminated NCT00124709 Phase 4 Pimecrolimus;Corticosteroid
40 Comparison of CL Wear Between Two Allergy Drops Withdrawn NCT00489398 Phase 4 epinastine HCL and olopatadine HCL
41 Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Unknown status NCT00298337 Phase 2, Phase 3 Mixture of probiotic bacteria and prebiotic oligosaccharide
42 A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis Unknown status NCT00812799 Phase 3 Oralgen
43 Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Unknown status NCT02560948 Phase 3
44 Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis Completed NCT00244543 Phase 3 R89674 (generic name not yet established)
45 Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis Completed NCT00241319 Phase 3 R89674 (generic name not yet established)
46 Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis Completed NCT00364091 Phase 3 R89674 0.025% ophthalmic solution
47 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
48 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
49 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model Completed NCT01479374 Phase 3 AL-4943A ophthalmic solution;AL-4943A vehicle;Olopatadine hydrochloride ophthalmic solution, 0.2%
50 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis Completed NCT01743027 Phase 3 AL-4943A ophthalmic solution;Olopatadine hydrochloride ophthalmic solution, 0.2%;Olopatadine hydrochloride ophthalmic solution, 0.1%;AL-4943A ophthalmic solution vehicle

Search NIH Clinical Center for Allergic Conjunctivitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: conjunctivitis, allergic

Genetic Tests for Allergic Conjunctivitis

Anatomical Context for Allergic Conjunctivitis

MalaCards organs/tissues related to Allergic Conjunctivitis:

39
Eye, Testes, Skin, T Cells, Bone, Endothelial, B Cells

Publications for Allergic Conjunctivitis

Articles related to Allergic Conjunctivitis:

(show top 50) (show all 591)
id Title Authors Year
1
Increased red cell distribution width levels in children with seasonal allergic conjunctivitis. ( 28523524 )
2017
2
Topical ocular treatment with monoclonal antibody Fab fragments targeting Japanese cedar pollen Cry j 1 inhibits Japanese cedar pollen-induced allergic conjunctivitis in mice. ( 28119075 )
2017
3
MiR-146a overexpression effectively improves experimental allergic conjunctivitis through regulating CD4(+)CD25(-)T cells. ( 28810531 )
2017
4
Allergic Conjunctivitis in Patients with Respiratory Allergic Symptoms; a Retrospective Study in Greece. ( 28428968 )
2017
5
Nitrite, neopterin levels and tryptophan degradation in allergic conjunctivitis. ( 28779270 )
2017
6
Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals. ( 28848937 )
2017
7
Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis. ( 27956527 )
2017
8
Superoxide dismutase 3 attenuates experimental Th2-driven allergic conjunctivitis. ( 28063939 )
2017
9
Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients. ( 28273659 )
2017
10
Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28046113 )
2017
11
Allergic conjunctivitis in Asia. ( 28487836 )
2017
12
Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge. ( 28593244 )
2017
13
Diagnosis and management of allergic conjunctivitis in pediatric patients. ( 28052798 )
2017
14
Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. ( 28656804 )
2017
15
Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study. ( 28630085 )
2017
16
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. ( 28652694 )
2017
17
Efficacy of oral immunotherapy with a rice-based edible vaccine containing hypoallergenic Japanese cedar pollen allergens for treatment of established allergic conjunctivitis in mice. ( 28676431 )
2017
18
Evaluation of allergic sensitization in Lebanese patients with allergic conjunctivitis. ( 28831678 )
2017
19
Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber. ( 28007090 )
2017
20
An inhibitor peptide of toll-like receptor 2 shows therapeutic potential for allergic conjunctivitis. ( 28246054 )
2017
21
Correction: Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28245290 )
2017
22
Novel oleyl amine-modified polymannuronic acid micelle loading tacrolimus for therapy of allergic conjunctivitis. ( 28655660 )
2017
23
Allergic Conjunctivitis and the Associated Risk of Migraine Among Children: A Nationwide Population-based Cohort Study. ( 27382919 )
2016
24
Development of Allergic Conjunctivitis Induced by House Dust Mite Extract From Dermatophagoides pteronyssinus. ( 27074380 )
2016
25
Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF. ( 26936233 )
2016
26
Topical Application of Interleukin-28A Attenuates Allergic Conjunctivitis in an Ovalbumin-Induced Mouse Model. ( 26886894 )
2016
27
Topical Antihistamines and Mast Cell Stabilizers for Treating Allergic Conjunctivitis. ( 27281835 )
2016
28
Efficacy and safety of an eye wash solution in allergic conjunctivitis after conjunctival allergen challenge. ( 27788889 )
2016
29
Ocular Pharmacology of Tear Film, Dry Eye, and Allergic Conjunctivitis. ( 27913889 )
2016
30
Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. ( 26770669 )
2016
31
Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis. ( 27720602 )
2016
32
Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis. ( 27221794 )
2016
33
TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model. ( 27726468 )
2016
34
Ambient air pollution, weather changes, and outpatient visits for allergic conjunctivitis: A retrospective registry study. ( 27033635 )
2016
35
High incidence of dry eye in young children with allergic conjunctivitis in Southwest China. ( 27226346 )
2016
36
Expression of TSLP and Downstream Molecules IL-4, IL-5, and IL-13 on the Eye Surface of Patients with Various Types of Allergic Conjunctivitis. ( 27504196 )
2016
37
Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. ( 27869354 )
2016
38
Topical Administration of I^-1,3-Glucan to Modulate Allergic Conjunctivitis in a Murine Model. ( 27002295 )
2016
39
Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. ( 27192186 )
2016
40
Risk of Allergic Rhinitis, Allergic Conjunctivitis, and Eczema in Children Born to Mothers with Gum Inflammation during Pregnancy. ( 27224053 )
2016
41
Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. ( 27466061 )
2016
42
Role of macrophage migration inhibitory factor (MIF) in pollen-induced allergic conjunctivitis and pollen dermatitis in mice. ( 25647395 )
2015
43
Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. ( 26604594 )
2015
44
Sex hormones in allergic conjunctivitis: altered levels of circulating androgens and estrogens in children and adolescents with vernal keratoconjunctivitis. ( 25756057 )
2015
45
The C-C chemokine receptor 6 (CCR6) is crucial for Th2-driven allergic conjunctivitis. ( 26307432 )
2015
46
Immunomodulatory effects of galectin-1 on an IgE-mediated allergic conjunctivitis model. ( 25574053 )
2015
47
Does allergic conjunctivitis always require prescription eyedrops? ( 26651889 )
2015
48
Possible Mechanism of Action of the Antiallergic Effect of an Aqueous Extract of Heliotropium indicum L. in Ovalbumin-Induced Allergic Conjunctivitis. ( 26681960 )
2015
49
Mesenchymal stem cell secretome to control inflammation in allergic conjunctivitis. ( 27215000 )
2015
50
Estimating Seasonal Allergic Conjunctivitis Market Size And Spending. ( 26532791 )
2015

Variations for Allergic Conjunctivitis

Expression for Allergic Conjunctivitis

Search GEO for disease gene expression data for Allergic Conjunctivitis.

Pathways for Allergic Conjunctivitis

Pathways related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 37)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
2
Show member pathways
13.42 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
3
Show member pathways
13.28 CCL11 CXCL8 IL13 IL4 IL5 TLR3
4
Show member pathways
13.27 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
5
Show member pathways
12.69 CXCL8 ICAM1 IFNG IL13 IL33 IL4
6
Show member pathways
12.66 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
7
Show member pathways
12.49 IFNG IL13 IL4 IL5
8
Show member pathways
12.21 CCL11 CXCL8 IFNG IL13 IL4 IL5
9
Show member pathways
12.15 IFNG IL13 IL4 IL5
10
Show member pathways
12.14 CXCL8 IFNG TLR3
11
Show member pathways
12.12 CCL11 CXCL8 IFNG IL4
12
Show member pathways
12.12 CXCL8 IFNG IL13 IL4 IL5
13 11.96 CXCL8 ICAM1 IFNG IL4
14 11.95 IFNG IL4 IL5 PTGDR2
15 11.95 CCL11 CXCL8 ICAM1 IL13 IL4
16
Show member pathways
11.93 IL13 IL5 TLR3
17
Show member pathways
11.84 IFNG IL4 TLR3
18 11.78 CXCL8 ICAM1 IFNG
19
Show member pathways
11.75 CXCL8 IFNG IL4 IL5
20 11.66 ICAM1 IL4 IL5
21 11.61 CCL11 IL4 IL5
22
Show member pathways
11.6 CXCL8 ICAM1 IFNG
23 11.57 CCL11 CXCL8 IL13 IL4 IL5
24 11.55 CXCL8 ICAM1 IFNG IL13 IL4 IL5
25 11.52 CXCL8 ICAM1 IL13 IL4
26 11.49 CXCL8 ICAM1 IFNG
27 11.44 CXCL8 ICAM1 IFNG
28 11.34 IFNG IL13 IL33 IL4 IL5 PTGDR2
29 11.29 IFNG IL4 IL5
30 11.26 IFNG IL13 IL4 IL5
31 11.16 CCL11 CXCL8 IL13 IL4 IL5
32 11.16 IFNG IL13 IL33 IL4 IL5
33 11.15 IFNG IL13 IL4 IL5
34 11.12 IFNG IL13
35 11.06 ICAM1 IFNG
36 10.9 IL13 IL4 IL5
37 10.77 CCL11 IFNG IL13 IL33 IL4 IL5

GO Terms for Allergic Conjunctivitis

Cellular components related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CCL11 CXCL8 IFNG IL13 IL33 IL4
2 external side of plasma membrane GO:0009897 9.46 ICAM1 IFNG IL13 IL4
3 extracellular space GO:0005615 9.28 CCL11 CXCL8 ICAM1 IFNG IL13 IL33

Biological processes related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.85 IFNG IL33 TLR3
2 positive regulation of protein phosphorylation GO:0001934 9.84 IFNG IL4 TLR3
3 cellular response to lipopolysaccharide GO:0071222 9.82 CXCL8 ICAM1 IFNG
4 cellular response to tumor necrosis factor GO:0071356 9.81 CCL11 CXCL8 ICAM1
5 response to ethanol GO:0045471 9.81 ICAM1 IL13 IL4
6 response to virus GO:0009615 9.8 CCL11 IFNG TLR3
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 ICAM1 IL4 IL5
8 movement of cell or subcellular component GO:0006928 9.76 CXCL8 IFNG IL13
9 cellular response to interleukin-1 GO:0071347 9.73 CCL11 CXCL8 ICAM1
10 neutrophil chemotaxis GO:0030593 9.72 CCL11 CXCL8 IFNG
11 cellular response to interferon-gamma GO:0071346 9.69 CCL11 ICAM1 TLR3
12 positive regulation of interleukin-12 production GO:0032735 9.67 IFNG TLR3
13 chemotaxis GO:0006935 9.67 CCL11 CXCL8 IL4 PTGDR2
14 innate immune response in mucosa GO:0002227 9.66 IL4 RNASE3
15 negative regulation of osteoclast differentiation GO:0045671 9.65 IL4 TLR3
16 defense response to protozoan GO:0042832 9.65 IFNG IL4
17 extrinsic apoptotic signaling pathway GO:0097191 9.65 IFNG IL33 TLR3
18 positive regulation of macrophage activation GO:0043032 9.64 IL13 IL33
19 positive regulation of B cell proliferation GO:0030890 9.63 IL13 IL4 IL5
20 inflammatory response GO:0006954 9.63 CCL11 CXCL8 HRH1 IL13 IL5 TLR3
21 positive regulation of immunoglobulin secretion GO:0051024 9.62 IL33 IL5
22 positive regulation of mast cell degranulation GO:0043306 9.62 IL13 IL4
23 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IFNG IL4
24 positive regulation of immunoglobulin production GO:0002639 9.6 IL13 IL4
25 eosinophil chemotaxis GO:0048245 9.59 CCL11 HRH1
26 positive regulation of interleukin-13 production GO:0032736 9.58 IL33 IL4
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.57 IFNG IL4
28 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.54 IFNG IL4
29 type 2 immune response GO:0042092 9.52 IL33 IL4
30 negative regulation of endothelial cell apoptotic process GO:2000352 9.5 ICAM1 IL13 IL4
31 regulation of proton transport GO:0010155 9.49 IL13 IL4
32 negative regulation of complement-dependent cytotoxicity GO:1903660 9.43 IL13 IL4
33 microglial cell activation GO:0001774 9.43 IL13 IL4 TLR3
34 microglial cell activation involved in immune response GO:0002282 9.4 IL33 TLR3
35 immune response GO:0006955 9.17 CCL11 CXCL8 IFNG IL13 IL4 IL5
36 positive regulation of chemokine biosynthetic process GO:0045080 9.13 IFNG IL4 TLR3

Molecular functions related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL11 CXCL8 IFNG IL13 IL33 IL4
2 cytokine receptor binding GO:0005126 8.96 IL13 IL4

Sources for Allergic Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....